LEADER 05106nam 2201201z- 450 001 9910557489703321 005 20231214132828.0 035 $a(CKB)5400000000042934 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77051 035 $a(EXLCZ)995400000000042934 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNon-small Cell Lung Cancer: Current Therapies and New Targeted Treatments 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (258 p.) 311 $a3-0365-0130-4 311 $a3-0365-0131-2 330 $aConventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied. 517 $aNon-small Cell Lung Cancer 606 $aMedicine$2bicssc 610 $anon-small cell lung cancer 610 $apreviously treated patients 610 $aphase I/II trial 610 $achemotherapy 610 $adocetaxel 610 $aS-1 610 $aimmunotherapy 610 $arechallenge 610 $aretrospective analysis 610 $apulmonary pleomorphic carcinoma 610 $aprognostic factor 610 $aglucose transporter 1 610 $alung cancer 610 $amultiple cancers 610 $ametastasis 610 $asequencing 610 $amutation 610 $agenomic diagnosis 610 $aFDG-PET 610 $aimmune checkpoint inhibitor 610 $aPD-1 610 $aprognosis 610 $aRAD51B methylation 610 $aPD-L1 expression 610 $apredictive biomarker 610 $aPD-1 blockade 610 $ainterstitial lung disease 610 $apulmonary fibrosis 610 $aradiology and other imaging 610 $anon-small-cell lung cancer 610 $aepidermal growth factor receptor 610 $atyrosine kinase inhibitors 610 $aTP53 mutations 610 $aresponsiveness 610 $atargeted therapy 610 $anetwork meta-analysis 610 $astage IIIA-N2 610 $asurgery 610 $aimmune checkpoint inhibitors 610 $abiomarker 610 $anonsmall cell lung cancer 610 $aHIP1R 610 $aPD-L1 610 $aRUNX1 610 $amethylation 610 $asurvival 610 $aEGFR-TKI 610 $aT790M 610 $aosimertinib 610 $aimmune-related adverse events 610 $aendocrine disorders 610 $atumor-bearing patients 610 $aPD-1 inhibitors 610 $aPD-L1 inhibitors 610 $ameta-analysis 610 $anivolumab 610 $aExpanded Access Program 610 $areal-world data 610 $adaily practice 610 $aprognostic factors 610 $aNSCLC 610 $aKRAS 610 $aDNA polymerase beta 610 $aplatinum-based first-line 610 $aadjuvant chemotherapy 610 $a?-catenin 610 $alung neoplasms 610 $anucleotide-diphosphate kinase 610 $arecurrence 610 $aunresectable 610 $asalvage surgery 610 $aoligometastasis 615 7$aMedicine 700 $aUchino$b Junji$4edt$01302981 702 $aUchino$b Junji$4oth 906 $aBOOK 912 $a9910557489703321 996 $aNon-small Cell Lung Cancer: Current Therapies and New Targeted Treatments$93026799 997 $aUNINA